Antioxidant therapy for the treatment of pulmonary hypertension

Antioxidants and Redox Signaling

Volumn 18, Issue 14, 2013, Pages 1723-1726

  Suzuki, Yuichiro J ^a   Steinhorn, Robin H ^b   Gladwin, Mark T ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; AZATHIOPRINE; CATALASE; FEBUXISTAT; FLAVONOID; GLUTAREDOXIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; NITROGEN DIOXIDE; OXIDOREDUCTASE; PEROXIREDOXIN; PREDNISONE; REACTIVE NITROGEN SPECIES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SUPEROXIDE DISMUTASE; THIOCTIC ACID; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; EXTRACORPOREAL OXYGENATION; FIBROSING ALVEOLITIS; HEART AFTERLOAD; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREMATURE LABOR; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW;

ANTIOXIDANTS; HUMANS; HYPERTENSION, PULMONARY;

ANIMALIA;

EID: 84875917394     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5193     Document Type: Review

References (9)

1. Bueno M, Wang J, Mora AL, and Gladwin MT. Nitrite signaling in pulmonary hypertension: mechanisms of bioacti-vation, signaling and therapeutics. Antioxid Redox Signal 18: 1797-1809, 2013.
2. Fike CD, Dikalova A, Slaughter JC, Kaplowitz MR, Zhang Y, and Aschner JL. Reactive oxygen species reducing strategies improve pulmonary arterial responses to nitric oxide in piglets with chronic hypoxia-induced pulmonary hypertension. Antioxid Redox Signal 18: 1727-1738, 2013.
3. Norton CE, Broughton BRS, Jernigan NL, Walker BR, and Resta TC. Enhanced depolarization-induced pulmonary va-soconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2. Antioxid Redox Signal 18: 1777-1788, 2013.
4. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 11: S79-S84, 2010.
5. Sun X, Sharma S, Fratz S, Kumar S, Rafikov R, Aggarwal S, Rafikova O, Lu Q, Burns T, Dasarathy S, Wright J, Schreiber C, Radman M, Fineman JR, and Black SM. Disruption of endothelial cell mitochondrial bioenergetics in lambs with increased pulmonary blood flow. Antioxid Redox Signal 18: 1739-1752, 2013.
6. Villegas LR, Kluck D, Field C, Oberley-Deegan RE, Woods C, Yeager ME, El Kasmi KC, Savani RC, Bowler RP, and Nozik-Grayck E. Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid Redox Signal 18: 1753-1764, 2013.
7. Voelkel NF, Bogaard HJ, al Husseini A, Farkas L, Gomez-Arroyo J, and Natarajan R. Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension? Antioxid Redox Signal 18: 1810-1817, 2013.
8. phox/Nox4 expression is involved in remodeling through hydrogen peroxide signaling in experimental persistent pulmonary hypertension of the newborn. Antioxid Redox Signal 18: 1765-1776, 2013.
9. Wong C, Bansal G, Pavlickova L, Marcocci L, and Suzuki YJ. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal 18: 1789-1796, 2013.